This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Teva Pharmaceutical Industries Ltd.
Drug Names(s): tiagabine hydrochloride
Description: The precise mechanism by which Gabitril exerts its antiseizure effect is unknown, although it is believed to be related to its ability, documented in in vitro experiments, to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. These experiments have shown that Gabitril binds to recognition sites associated with the GABA uptake carrier. It is thought that, by this action, Gabitril blocks GABA uptake into presynaptic neurons, permitting more GABA to be available for receptor binding on the surfaces of post-synaptic cells. Inhibition of GABA uptake has been shown for synaptosomes, neuronal cell cultures, and glial cell cultures. In rat-derived hippocampal slices, Gabitril has been shown to prolong GABA-mediated inhibitory post-synaptic potentials. Gabitril increases the amount of GABA available in the extracellular space of the globus pallidus, ventral palladum, and substantia nigra in rats at the ED50 and ED85 doses for inhibition of pentylenetetrazol (PTZ)-induced tonic seizures. This suggests that Gabitrilprevents the propagation of neural impulses that contribute to seizures by a GABA-ergic action.
Teva no longer reports for Gabitril as of Q3 2011.
Tiagabine was discovered by Novo Nordisk.
Abbott and Novo Nordisk
In 1990, Abbott signed a licensing agreement with Novo Nordisk to develop and market Gabitril in the U.S., Canada and Mexico.
In December 1997, Abbott Laboratories and Novo Nordisk announced the signing of an agreement for Gabitril that will expand Abbott's licensed territory to include Latin America. Under terms of the agreement, Abbott will be responsible for product registration, sales and marketing in all of Latin America. Financial terms ofthe agreement were not disclosed.
Sanofi and Novo Nordisk
Also in December 1997, Novo Nordisk announced that it out-licensed Gabitril worldwide except for the Americas and Japan to Sanofi. Providing satisfactory due diligence the agreement will be effective as of January 15, 1998. After March 1, 1998, Sanofi will take over all marketing and promotion activities. The two companies...See full deal structure in Biomedtracker
Partners: AbbVie Inc. Sanofi Novo Nordisk A/S
Pink Sheet In Brief: Abbott Gabitril
Pink Sheet In Brief: Novo Nordisk
Additional information available to subscribers only: